中华临床医师杂志(电子版)
中華臨床醫師雜誌(電子版)
중화림상의사잡지(전자판)
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2014年
3期
426-429
,共4页
唐仪%杨厚林%吴少杰%方主亭%陈良生
唐儀%楊厚林%吳少傑%方主亭%陳良生
당의%양후림%오소걸%방주정%진량생
结直肠肿瘤%肿瘤转移%化学疗法,肿瘤,局部灌注%治疗效果%FOLFOX4
結直腸腫瘤%腫瘤轉移%化學療法,腫瘤,跼部灌註%治療效果%FOLFOX4
결직장종류%종류전이%화학요법,종류,국부관주%치료효과%FOLFOX4
Colorectal neoplasms%Neoplasms metastasis%Chemotherapy,cancer,regional perfusion%Treatment outcome%FOLFOX4
目的:探讨经肝动脉置管化疗栓塞对不可切除的结肠癌肝转移(CRCLM)肝内转移灶的疗效。方法回顾性分析不可切除的CRCLM在2010年6月至2013年6月采用超选择经肝动脉置管化疗栓塞术41例患者,和2007年3月至2010年5月单纯经肝动脉灌注化疗栓塞50例患者,比较各组之间的疗效、有效率、临床获益率及不良反应。结果肝动脉置管化疗栓塞组和肝动脉灌注化疗栓塞组的有效率分别是56.1%和38.0%,临床获益率分别是87.8%和66.0%,差异有统计学意义(P<0.05)。两组患者的化疗不良反应以白细胞下降、恶心呕吐、末梢神经炎、静脉炎、腹泻和口腔黏膜炎为主。两组间不良反应的比较差异无统计学意义(P>0.05)。结论经肝动脉置管FOLFOX4方案化疗栓塞术治疗不可切除的CRCLM有一定的疗效,其有效率和临床获益率较单纯的肝动脉化疗栓塞术有优势。
目的:探討經肝動脈置管化療栓塞對不可切除的結腸癌肝轉移(CRCLM)肝內轉移竈的療效。方法迴顧性分析不可切除的CRCLM在2010年6月至2013年6月採用超選擇經肝動脈置管化療栓塞術41例患者,和2007年3月至2010年5月單純經肝動脈灌註化療栓塞50例患者,比較各組之間的療效、有效率、臨床穫益率及不良反應。結果肝動脈置管化療栓塞組和肝動脈灌註化療栓塞組的有效率分彆是56.1%和38.0%,臨床穫益率分彆是87.8%和66.0%,差異有統計學意義(P<0.05)。兩組患者的化療不良反應以白細胞下降、噁心嘔吐、末梢神經炎、靜脈炎、腹瀉和口腔黏膜炎為主。兩組間不良反應的比較差異無統計學意義(P>0.05)。結論經肝動脈置管FOLFOX4方案化療栓塞術治療不可切除的CRCLM有一定的療效,其有效率和臨床穫益率較單純的肝動脈化療栓塞術有優勢。
목적:탐토경간동맥치관화료전새대불가절제적결장암간전이(CRCLM)간내전이조적료효。방법회고성분석불가절제적CRCLM재2010년6월지2013년6월채용초선택경간동맥치관화료전새술41례환자,화2007년3월지2010년5월단순경간동맥관주화료전새50례환자,비교각조지간적료효、유효솔、림상획익솔급불량반응。결과간동맥치관화료전새조화간동맥관주화료전새조적유효솔분별시56.1%화38.0%,림상획익솔분별시87.8%화66.0%,차이유통계학의의(P<0.05)。량조환자적화료불량반응이백세포하강、악심구토、말소신경염、정맥염、복사화구강점막염위주。량조간불량반응적비교차이무통계학의의(P>0.05)。결론경간동맥치관FOLFOX4방안화료전새술치료불가절제적CRCLM유일정적료효,기유효솔화림상획익솔교단순적간동맥화료전새술유우세。
Objective To investigate the effect of hepatic arterial cathetering chemoembolization on patients with unresectable colorectal liver metastases. Methods 41 cases of unresectable colorectal liver metastases from June 2010 to June 2013 who were treated by hepatic artery cathetering chemoembolization were compared with 50 cases from March 2007 to May 2010 who undergo via hepatic artery perfusion chemoembolization.The amount of effective rate, clinical benefit rate and adverse reaction were compared between two groups. Results The amount of effective rate and clinical benefit rate were 56.1%, 87.8%, respectively, in the hepatic artery cathetering chemoembolization and 38.0%, 66.0%in the hepatic artery perfusion chemoembolization respectively. The differences were respectively statistically significant(P<0.05). Adverse reaction of chemotherapy include white blood cells decline, nausea, vomiting, peripheral neuritis, phlebitis, diarrhea, and oral mucositis.The adverse reaction between the two groups has no statistical significance(P>0.05). Conclusion Patients with unresectable colorectal liver metastases can benefit from hepatic arterial cathetering FOLFOX4 chemotherapy and embolization, especially in the effective rate and clinical benefit rate.